Elusys delivers first shipment of ANTHIM®, its treatment for Inhalational Anthrax, to U.S. Government Strategic National Stockpile

Media Center PRESS RELEASE 2017 ELUSYS DELIVERS FIRST SHIPMENT OF ANTHIM®, ITS TREATMENT FOR INHALATION ANTHRAX, TO THE U.S. GOVERNMENT STRATEGIC NATIONAL STOCKPILE Anthim Lyophilization Program Continues to Advance PINE BROOK, NJ, OCTOBER 10, 2017 – Elusys Therapeutics, Inc. (Elusys) announced today that the company has delivered the first doses of ANTHIM® (obiltoxaximab) Injection, its treatment […]

Elusys Receives $16.35 Million for Delivery of ANTHIM® to U.S. Government

Media Center PRESS RELEASE 2017 ELUSYS RECEIVES $16.35 MILLION FOR DELIVERY OF ANTHIM® TO U.S. GOVERNMENT ELUSYS awarded additional $5 million to complete development of novel lyophilized form of ANTHIM PINE BROOK, NJ, JANUARY 24, 2017 – Elusys Therapeutics, Inc. (Elusys) today announced it has received $16.35 million for completing the second delivery of ANTHIM®, (obiltoxaximab) Injection, its treatment for […]